Donald Thomas, MD
Rheumatology · Greenbelt, MDNPI 1730167545
Payments from drug & device makers
Across 643 payments — averaging $731.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$301K
- AstraZeneca$145K
- Aurinia Pharma U.S., Inc.$12K
- Genentech USA, Inc.$7K
- Johnson & Johnson$1K
- Mallinckrodt Hospital Products Inc.$1K
- plus $4K from 22 others
What the payments were for
- Consulting fees$74,76916%
- Speaking & faculty fees$320,78268%
- Travel & lodging$61,49213%
- Food & beverage$13,4823%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 284 | $300,906 |
| AstraZeneca(2 entities) | 149 | $144,950 |
| Aurinia Pharma U.S., Inc. | 16 | $11,528 |
| Genentech USA, Inc. | 16 | $7,167 |
| Johnson & Johnson | 23 | $1,233 |
| Mallinckrodt Hospital Products Inc. | 10 | $1,207 |
| Novartis | 19 | $1,101 |
| Amgen(2 entities) | 40 | $830 |
| AbbVie | 19 | $383 |
| ANI Pharmaceuticals, Inc. | 4 | $233 |
| Pfizer | 13 | $189 |
| E.r. Squibb & Sons, L.L.C. | 10 | $170 |
| UCB, Inc. | 9 | $152 |
| Fresenius Kabi USA, LLC | 7 | $125 |
| Pacira Pharmaceuticals Incorporated | 4 | $80 |
| Hikma Pharmaceuticals USA | 3 | $47 |
| Radius Health, Inc. | 2 | $45 |
| Merck | 3 | $42 |
| Sanofi | 2 | $40 |
| Sandoz | 1 | $33 |
| Sobi, Inc | 2 | $33 |
| Invivyd Inc | 1 | $25 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Fidia Pharma USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$269,223
- SAPHNELO$130,873
- LUPKYNIS$9,780
- ACTHAR$960
- STELARA$800
- SIMPONI ARIA$800
- PURIFIED CORTROPHIN GEL$164
- KRYSTEXXA$145
How this compares
$470,632 in reported general payments places this provider in the 90th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $307,144 |
| RinvoqUpadacitinib | 35 | $277,440 |
| BenlystaBelimumab | 34 | $202,972 |
| OrenciaAbatacept/Maltose | 28 | $159,758 |
| Xeljanz XrTofacitinib Citrate | 21 | $133,189 |
| Enbrel SureclickEtanercept | 11 | $111,189 |
| SimponiGolimumab | 11 | $92,480 |
| KevzaraSarilumab | 13 | $55,221 |
| OlumiantBaricitinib | 13 | $39,989 |
| TymlosAbaloparatide | 11 | $34,060 |
| Teriparatide | 15 | $33,274 |
| RestasisCyclosporine | 14 | $20,371 |
| Hydroxychloroquine Sulfate | 260 | $12,422 |
| RasuvoMethotrexate/Pf | 17 | $11,539 |
| Cyclosporine | 20 | $7,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Restasis | $383 | $297,81149 claims |
| GSKBenlysta | $300,906 | $202,97234 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $170 | $159,75828 claims |
| Johnson & JohnsonSimponi | $1,233 | $92,48011 claims |
| SanofiKevzara | $40 | $55,22113 claims |
| Radius Health, Inc.Tymlos | $45 | $34,06011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 173 rheumatology providers in Maryland.
Other rheumatology in Greenbelt
- Steven KleinHagerstown$3.4M
- Herbert BarafWheaton$1.4M
- Paul DemarcoWheaton$1.4M
- Thomas Grader BeckBaltimore$1.2M
- Michelle PetriBaltimore$1.1M
- Laura HummersBaltimore$1M
- Alan MatsumotoWheaton$720K
- Evan SiegelRockville$624K
- Jeffrey PotterWheaton$477K
- Edmund MaclaughlinEaston$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.